Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
70
Recruiting, any sponsor type, condition "thyroid cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed245
70 trials
Showing 1 to 25, recently updated first.
- Studies on Tumors of the ThyroidRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001160 · 2,500 participants (planned) · Start Jun 1, 1977
Drug: 68-Gallium Dotatate · For: Hurthle Cell Thyroid Cancer; Tall Cell Variant Thyroid Cancer; Follicular Thyroid Cancer and 2 more
Sites: Bethesda, Maryland
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT04927416 · 54 participants (planned) · Start Oct 25, 2021 · Primary completion Nov 30, 2030
Drug: 68-Gallium-DOTATATE-PET/CT · For: Metastic Thyroid Cancer
Sites: Bethesda, Maryland
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07470489 · 12 participants (planned) · Start Oct 29, 2026 · Primary completion Sep 1, 2030
Drug: Cemiplimab; Zanzalintinib · For: Anaplastic Thyroid Cancer
Sites: Houston, Texas
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT05786924 · 623 participants (planned) · Start Apr 18, 2023 · Primary completion Jun 2028
Drug: S241656; FOLFOX6/FOLFOX7 and 5 more · For: Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis and 29 more
Sites: Gilbert, Arizona; Los Angeles, California; San Francisco, California · 49 sites in all
- Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT06475989 · 264 participants (planned) · Start Dec 27, 2024 · Primary completion Sep 30, 2030
Drug: Cabozantinib; Dabrafenib and 1 more · For: Refractory Differentiated Thyroid Gland Carcinoma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Fort Smith, Arkansas · 307 sites in all
Thomas HopeAcademic, hospital or other
NCT06961084 · 62 participants (planned) · Start Dec 4, 2025 · Primary completion Apr 1, 2028
Drug: Iodine-124 · For: Thyroid Cancer
Sites: San Francisco, California
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03093909 · 44 participants (planned) · Start Nov 22, 2017 · Primary completion Nov 30, 2027
Drug: Gemcitabine · For: Malignant Neoplasm of Bone and Articular Cartilage; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Independent (Primary) Multiple Sites and 7 more
Sites: Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04589624 · 42 participants (planned) · Start Aug 12, 2020 · Primary completion May 31, 2027
Drug: Hyperpolarized Carbon C 13 Pyruvate · For: Thyroid Gland Carcinoma
Sites: Houston, Texas
Beijing Scitech-Mq Pharmaceuticals LimitedIndustry
NCT06359847 · 60 participants (planned) · Start Nov 15, 2023 · Primary completion Dec 2027
Drug: ST-1898 tablets · For: Differentiated Thyroid Carcinoma
Sites: Beijing, China
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06959511 · 45 participants (planned) · Start Jul 22, 2025 · Primary completion Mar 1, 2028
Drug: Zanzalintinib · For: Neoadjuvant Treatment; Thyroid Cancer
Sites: Boston, Massachusetts; Ann Arbor, Michigan; Cleveland, Ohio · 5 sites in all
- Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid CancerPivotal-lookingRecruiting
Vanderbilt University Medical CenterAcademic, hospital or other
NCT05999630 · 100 participants (planned) · Start Aug 21, 2023 · Primary completion Dec 31, 2027
Drug: Artificial Tears Methylcellulose · For: Nasolacrimal Duct Obstruction; Thyroid Cancer
Sites: Nashville, Tennessee
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid CancerRecruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT03841617 · 30 participants (planned) · Start Jul 29, 2019 · Primary completion Nov 1, 2035
Drug: Thyrogen · For: Thyroid Cancer
Sites: Bethesda, Maryland
- Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid CancerPivotal-lookingRecruiting
Medical University of BialystokAcademic, hospital or other
NCT05468554 · 160 participants (planned) · Start Nov 1, 2022 · Primary completion Jan 31, 2028
Drug: metformin · For: Thyroid Cancer
Sites: Bialystok, Poland; Kielce, Poland
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT05783323 · 13 participants (planned) · Start Feb 14, 2024 · Primary completion Oct 1, 2028
Drug: Larotrectinib monotherapy · For: Differentiated Thyroid Cancer; Pediatric Cancer; Cancer and 1 more
Sites: San Francisco, California; Boston, Massachusetts; Philadelphia, Pennsylvania · 6 sites in all
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsPivotal-lookingRecruiting
ModeX Therapeutics, An OPKO Health CompanyIndustry
NCT06239194 · 330 participants (planned) · Start Jun 12, 2024 · Primary completion Aug 2028
Drug: MDX2001 · For: Biliary Tract Cancer; Breast Cancer; Cervical Cancer and 18 more
Sites: Denver, Colorado; Miami, Florida; Boston, Massachusetts · 6 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06007924 · 30 participants (planned) · Start Aug 16, 2023 · Primary completion Aug 16, 2027
Drug: Avutometinib; Defactinib · For: Thyroid Cancer
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT07874321 · 39 participants (planned) · Start Sep 20, 2026 · Primary completion Dec 31, 2027
Drug: Becotatug Vedotin (MRG003); Lenvatinib and 1 more · For: Thyroid Cancer; Tumor; Advanced Thyroid Carcinoma
Sites: Guangzhou, China
University of ArizonaAcademic, hospital or other
NCT06814496 · 30 participants (planned) · Start Sep 8, 2025 · Primary completion May 2030
Drug: Tarlatamab · For: Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma and 8 more
Sites: Gilbert, Arizona; Tucson, Arizona; Seattle, Washington
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT06902376 · 12 participants (planned) · Start Jun 3, 2025 · Primary completion Mar 31, 2028
Drug: Cemiplimab; XL092 · For: Anaplastic Thyroid Cancer; Thyroid Cancer; BRAF Mutation-Related Tumors
Sites: Boston, Massachusetts; Chapel Hill, North Carolina
Novartis PharmaceuticalsNovartis (NVS)
NCT07006727 · 116 participants (planned) · Start Oct 16, 2025 · Primary completion Aug 29, 2031
Drug: 225Ac-ETN029; 111In-ETN029 · For: Small Cell Lung Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; Neuroendocrine Prostate Cancer and 8 more
Sites: Iowa City, Iowa; Boston, Massachusetts; Royal Oak, Michigan · 8 sites in all
- Sacituzumab govitEcan in THYroid CancersRecruiting
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
NCT06235216 · 42 participants (planned) · Start Sep 13, 2024 · Primary completion Dec 2027
Drug: Sacituzumab govitecan · For: Differentiated Thyroid Cancer; Anaplastic Thyroid Cancer
Sites: Barcelona, Spain; Ferrol, Spain; Hospitalet de Llobregat (Barcelona), Spain · 11 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT03647358 · 75 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 2027
Drug: Iodine-124 · For: Thyroid Carcinoma; Metastatic Thyroid Carcinoma
Sites: New York, New York
- The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid TumorsRecruiting
FindCure Biosciences (ZhongShan) Co., Ltd.Industry
NCT07459283 · 10 participants (planned) · Start Apr 20, 2026 · Primary completion Dec 2026
Drug: INN805 · For: Maligant Solid Tumor; Head & Neck Cancer; Thyroid Cancer and 3 more
Sites: Wuxi, China
The First Affiliated Hospital of Bengbu Medical UniversityAcademic, hospital or other
NCT03177902 · 400 participants (planned) · Start Jun 4, 2017 · Primary completion Apr 2027
Drug: Chemotherapy · For: Breast Cancer Female; Thyroid Gland
Sites: Bengbu, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.